Dallas, Texas 05/05/2014 (FINANCIALSTRENDS) – Synta Pharmaceuticals Corp. (NASDAQ:SNTA) the biopharma company which has been focussed on developing small molecule based therapies. The company has reported that it will now announce the first quarter results of 2014 by the May 8, 2014, Thursday.
It is expected that the pharma-giant will beat estimates give the spate of run it has had on recent fund raising spree it has been involved in, in the previous weeks.
The first of these was the sale of common stock which included over 1,250,000 shares which were common stock, priced t $4.01 per share. The management expect to earn over $5.0 million through the sale of such assets. These are approximate figures which the company is expected to achieve following the deduction of expenses payable and other deductions.
What will SNTA do with the results?
SNTA has been strategic on forward growth aspects in recent times. The proceeds of the sale will now allow SNTA to look at sections of its business it has been long been considering to focus better on – Research and development. The funds will also be effectively used in the development of clinical trials, intellectual property as well as manufacturing and looking at protective standards to Intellectual properties it currently owns.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)has been in the news for some time now with news of its common stock sale. The company has definitely been on the upward rally, thanks to deft handling of core issues by the company.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has been focused on developing therapies which are focused on commercial technology of small molecule drugs which will allow patients suffering from medical conditions of the types of cancer as well as chronic inflammation nature of diseases. The USP of SNTA is its rich and varied collection of chemical compounds as well as a sophisticated process of discover engine.